The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
about
Severe anaemia is not associated with HIV-1 env gene characteristics in Malawian childrenFrequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switchThe Antibody Response against HIV-1Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsFunctional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentMutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Appreciating HIV type 1 diversity: subtype differences in Env.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 envelope subregion length variation during disease progressionComparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesBroad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeEscape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesR5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domainThe genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.In vivo emergence of HIV-1 highly sensitive to neutralizing antibodiesThe presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionThe Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Specificity of the autologous neutralizing antibody response
P2860
Q21261525-3C747162-BAC6-4515-AF07-91F7517872F6Q24672335-FC29FFDD-B810-462F-BB90-0CD6C67B9C38Q27000889-DBB12417-2918-443D-BDBE-67C4C34053DFQ27489000-A2ADADDC-C6E9-4506-9081-152C7BB2EE98Q27644478-D3B50E80-768F-4A15-8EB5-2FAC695BC8ECQ27650903-03BEEE93-533A-4760-9F21-6E4801E3006BQ27677941-2208F590-1053-4542-9130-ED053EB45031Q27681527-6A047B63-D7C1-4474-9A0B-8AB90431FF69Q28483205-F0833DE4-8582-4A76-8594-66BFDD9E6B07Q28485983-1CEDE33A-9CF5-4377-BC59-3475A61B3BC7Q28728517-73AD3E53-13C7-47D1-805F-697F203FB893Q28752503-3D7A612F-8562-49B0-AF53-8F728BBCF857Q30355260-19B10CB4-A0B7-4A09-A9F7-F0B5AFFC0AE5Q30368471-4F771387-0EB6-425E-8E43-452D0D150DD5Q30375834-5AB3A648-6FB3-4173-AAAA-29028EB4A119Q30379200-13CF46B3-196B-4718-A9C3-F4B056F9AE09Q30397933-D84D7EF6-80D5-4789-9E21-0436FCDCB885Q30994182-3027D916-9071-4DD9-B22D-14FDEF58C230Q33417195-815767E7-6193-4069-BC01-3F2B80D5B7DFQ33504599-1FBDCC55-C456-44C5-9776-5969BC000B0BQ33504604-3F0E0900-348B-4DBA-BCA3-D73D57CE5208Q33518005-CC2B900E-7DA9-44FE-B7A1-83321D60C782Q33614461-F8FCF5A7-629C-4BD4-B6BE-B4B17EDEDFCCQ33640144-69DCD13C-268C-4D6C-A1D9-CF77B6271977Q33788792-B3791E6F-666C-489A-9F82-42986996E7A0Q33810849-2BA94B1C-9E19-4F29-AA56-E06221459BAEQ33826682-7BD5DE76-E525-4C1D-924A-D6A34870ABB5Q33839456-0DA82E99-99B0-421E-9165-8373570DE1E2Q33883887-E0A9FB2C-1497-40DA-B8F9-FEF8555E53C6Q33883936-39587936-79B1-442C-BA5A-184B94B152B4Q34009730-5538F967-2EFC-43BE-BFD9-87A8D16CA593Q34017550-DB946B3F-8409-4EAA-B5DC-8BB92E1D159CQ34085098-75BBF99F-6C2A-46D3-AF5F-8F34EDBBAE0BQ34120088-B37A7E2C-C1FA-48DD-8C39-5C90ECC0B347Q34300812-D262028E-55B2-42D3-8E12-5900F37EEB13Q34303849-9FD9695C-58CA-4D31-A851-B3E774A2E608Q34309493-D144E8E4-47CF-458B-8F70-8254C4D4BB04Q34397758-1CEC396B-8A5D-40E2-8AD1-650487B64CFFQ34406977-4CEFFF2B-2C8A-4794-9ECB-DEC6B8D81DEFQ34415389-41FA14C9-A898-4AE9-AB5C-CE7CFA0A3440
P2860
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@ast
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@en
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@nl
type
label
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@ast
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@en
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@nl
prefLabel
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@ast
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@en
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@nl
P2093
P2860
P1433
P1476
The V1/V2 domain of gp120 is a ...... mmonly induced upon infection.
@en
P2093
Abraham Pinter
Miroslaw K Gorny
Samuel C Kayman
Susan Zolla-Pazner
William J Honnen
P2860
P304
P356
10.1128/JVI.78.10.5205-5215.2004
P407
P577
2004-05-01T00:00:00Z